Ignite Creation Date:
2024-05-06 @ 7:13 PM
Last Modification Date:
2024-10-26 @ 3:02 PM
Study NCT ID:
NCT05935085
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-05
First Post:
2023-06-06
Brief Title:
This Study Will Evaluate the Safety Tolerability and Efficacy of ANB032 in Subjects With Moderate to Severe Atopic Dermatitis AD
Sponsor:
AnaptysBio Inc
Organization:
AnaptysBio Inc
Study Overview
Official Title:
A Phase 2 Randomized Double Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects With Moderate to Severe Atopic Dermatitis
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the safety tolerability and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis AD
Detailed Description:
This is a Phase 2 randomized double blind placebo controlled parallel group multicenter study to evaluate the safety tolerability efficacy pharmacokinetics and immunogenicity of ANB032 in subjects with moderate to severe atopic dermatitis AD
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None